[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354231-105":59,"doc-detail-354231-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","ca9-targeted-liposomal-delivery-of-siets1-inhibits-clear-cell-renal-cell-carcinoma-progression-by-disrupting-the-ets1myc-regulatory-axis-original-research","CA9-Targeted Liposomal Delivery of siETS1 Inhibits Clear Cell Renal Cell Carcinoma Progression by Disrupting the ETS1/MYC Regulatory Axis - Original Research","","Clear cell renal cell carcinoma (ccRCC) is an aggressive malignancy with high recurrence and limited treatment options, motivating development of more selective therapies. Carbonic anhydrase IX (CA9) is characteristically overexpressed on ccRCC cells, enabling site-specific delivery. Using TCGA and single-cell RNA sequencing, the study identifies the ETS1/MYC regulatory axis as a key driver. CA9-targeted liposomal nanoparticles loaded with siETS1 (ETS1@Lip-CAIX) silence ETS1/MYC and inhibit tumor growth across cell lines, patient-derived organoids, and nude mouse xenografts, with no major organ damage observed.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ca9-targeted-liposomal-delivery-of-siets1-inhibits-clear-cell-renal-cell-carcinoma-progression-by-disrupting-the-ets1myc-regulatory-axis-original-research/354231/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ca9-targeted-liposomal-delivery-of-siets1-inhibits-clear-cell-renal-cell-carcinoma-progression-by-disrupting-the-ets1myc-regulatory-axis-original-research/354231.png","ImageObject",300,407,{"name":92,"@type":93},"Stanley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is CA9 used as a targeting strategy in ccRCC?","Question",{"text":113,"@type":114},"CA9 is characteristically overexpressed on the surface of ccRCC cells, making it a promising target for site-specific drug delivery.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does ETS1 regulate MYC in this study?",{"text":118,"@type":114},"ChIP-PCR and dual-luciferase assays show ETS1 directly promotes MYC transcription through a specific binding site, establishing ETS1 as a transcriptional activator of MYC.",{"name":120,"@type":111,"acceptedAnswer":121},"What is ETS1@Lip-CAIX and how was it tested?",{"text":122,"@type":114},"ETS1@Lip-CAIX are siETS1-loaded liposomal nanoparticles surface-functionalized with a CA9-targeting peptide (CaIX-P7). Therapeutic efficacy was evaluated in ccRCC cell lines, patient-derived organoids, and nude mouse xenograft models.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},354231,1790200021,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336477405376,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","International Journal of Nanomedicine  \nOpen Access Full Text Article ORIGINAL RESEARCH  \nCA9-Targeted Liposomal Delivery of siETS1 Inhibits Clear Cell Renal Cell Carcinoma Progression by Disrupting the ETS1/MYC Regulatory Axis  \nYuyang Ye 1 , Jing Sun2 , Yizheng Zhang 1 , Shenghan Wang 3 , Zhaoqian Meng 4  \n1Department of Anesthesiology, The Second Qilu Hospital of ShanDong University, ShanDong University, Jinan, 250033, People’s Republic of China; 2Cheeloo College of Medicine, Shandong University, Jinan, 250012, People’s Republic of China; 3Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong First Medical University, Jinan, 250021, People’s Republic of China; 4Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, 250011, People’s Republic of China  \nCorrespondence: Zhaoqian Meng, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, 250011, People’s Republic of China, Tel +86 13940442192, Email [szymzq@163.com](szymzq@163.com)  \nBackground: Clear cell renal cell carcinoma (ccRCC) is a highly aggressive malignancy with a high rate of recurrence and limited therapeutic options. Carbonic anhydrase IX (CA9) is characteristically overexpressed on the surface of ccRCC cells, making it a promising target for site-specific drug delivery. However, identifying the key molecular drivers of ccRCC progression and developing efficient, targeted nanomedicines remain critical challenges in current research.  \nMethods: Bioinformatics analysis of TCGA and single-cell RNA sequencing data was used to elucidate the ETS1/MYC axis. Direct transcriptional regulation of MYC by ETS1 was experimentally validated by chromatin immunoprecipitation-quantitative PCR (ChIPPCR) and dual-luciferase reporter assays. An optimized CA9-targeting peptide, CaIX-P7, was designed via computational modeling and mutation screening, with affinity validated by surface plasmon resonance (SPR) . siETS1-loaded liposomal nanoparticles (LNPs) were prepared using microfluidics and surface-functionalized with CaIX-P7 (ETS1@Lip-CAIX) . The nanoparticles were characterized for size, zeta potential, and encapsulation efficiency. Therapeutic efficacy was evaluated in ccRCC cell lines (786-O, A-498), patientderived organoids (PDO), and nude mouse xenograft models.  \nResults: Single-cell analysis identified ETS1 and MYC as synergistically activated transcription factors within tumor epithelial cells. Mechanistically, ChIP-PCR and dual-luciferase assays demonstrated that ETS1 promotes MYC transcription through this specific binding site, establishing ETS1 as a direct transcriptional activator of MYC. The optimized peptide CaIX-P7 demonstrated superior binding affinity to CA9 (Kd=52.96 nM) compared to its precursor. The engineered ETS1@Lip-CAIX nanoparticles exhibited a stable size of 154.8 nm and high siRNA encapsulation efficiency (89.1%) . Systematic evaluation revealed that ETS1@Lip-CAIX effectively silenced the ETS1/MYC axis, leading to significant growth inhibition across all models, including patient-derived 3D organoids and in vivo xenografts, showed no discernible morphological alterations or pathological damage in major organs.  \nConclusion: This study identifies the ETS1/MYC axis as a novel therapeutic target in ccRCC. We further successfully developed a CA9-targeted nanoplatform, ETS1@Lip-CAIX, which exhibits robust anti-tumor efficacy by disrupting this newly discovered regulatory hub. These findings provide a foundation for future translational studies of ccRCC.  \nPlain Language Summary: Clear cell renal cell carcinoma (ccRCC) is the most aggressive and common type of kidney cancer. Despite improvements in surgery and existing drugs, many patients face high recurrence rates and limited treatment options. Through advanced data analysis and laboratory experiments, we identified ","cbCaieLQKyEOZFiJ","https://ap.wps.com/l/cbCaieLQKyEOZFiJ","pdf",13944223,23,"English","# Background\n## Methods\n## Results\n## Conclusion\n# Plain Language Summary\n## Clinical context and rationale\n## Targeting strategy and delivery platform\n## Experimental models and outcomes","[{\"question\":\"Why is CA9 used as a targeting strategy in ccRCC?\",\"answer\":\"CA9 is characteristically overexpressed on the surface of ccRCC cells, making it a promising target for site-specific drug delivery.\"},{\"question\":\"How does ETS1 regulate MYC in this study?\",\"answer\":\"ChIP-PCR and dual-luciferase assays show ETS1 directly promotes MYC transcription through a specific binding site, establishing ETS1 as a transcriptional activator of MYC.\"},{\"question\":\"What is ETS1@Lip-CAIX and how was it tested?\",\"answer\":\"ETS1@Lip-CAIX are siETS1-loaded liposomal nanoparticles surface-functionalized with a CA9-targeting peptide (CaIX-P7). Therapeutic efficacy was evaluated in ccRCC cell lines, patient-derived organoids, and nude mouse xenograft models.\"}]","CA9-Targeted Liposomal Delivery of siETS1 Inhibits Clear Cell Renal Cell Carcinoma Progression by Disrupting the ETS1/MYC Regulatory Axis - Original Research | PDF",1790109675,58,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c717da6418ce12c5fc7be1bd4e505264.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/79e4b5b2081417123c63b44f6608d7f9.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db4ab59ff20c291b40ff8bc5ea121ec6.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64aadcab664e202ba1cf5d53642a5728.webp",980,1268]